|
1
|
Siegel RL, Giaquinto AN and Jemal A:
Cancer statistics, 2024. CA Cancer J Clin. 74:12–49.
2024.PubMed/NCBI
|
|
2
|
Siegel RL, Kratzer TB, Giaquinto AN, Sung
H and Jemal A: Cancer statistics, 2025. CA Cancer J Clin. 75:10–45.
2025.PubMed/NCBI
|
|
3
|
Siegel RL, Kratzer TB, Wagle NS, Sung H
and Jemal A: Cancer statistics, 2026. CA Cancer J Clin.
76:e700432026.PubMed/NCBI
|
|
4
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
5
|
World Cancer Research Fund, . Pancreatic
cancer statistics. 2025.https://www.wcrf.org/preventing-cancer/cancer-statistics/pancreatic-cancer-statistics/
|
|
6
|
Hesami Z, Olfatifar M, Sadeghi A, Zali MR,
Mohammadi-Yeganeh S, Habibi MA, Ghadir MR and Houri H: Global trend
in pancreatic cancer prevalence rates through 2040: An
Illness-death modeling study. Cancer Med. 13:e703182024. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
National Cancer Institute, . SEER Cancer
Stat Facts: Pancreatic Cancer. Surveillance, Epidemiology, and End
Results (SEER) Program; Bethesda, MD: 2025, https://seer.cancer.gov/statfacts/html/pancreas.html
|
|
8
|
Stoop TF, Javed AA, Oba A, Koerkamp BG,
Seufferlein T, Wilmink JW and Besselink MG: Pancreatic cancer.
Lancet. 405:1182–1202. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Park W, Chawla A and O'Reilly EM:
Pancreatic cancer: A review. JAMA. 326:851–862. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang L, Sanagapalli S and Stoita A:
Challenges in diagnosis of pancreatic cancer. World J
Gastroenterol. 24:2047–2060. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Leng Q, Zhou J, Wang X, Zhang P, Xu H and
Cao D: HRS-4642 combined with nimotuzumab in the treatment of
recurrent or metastatic pancreatic ductal adenocarcinoma: Study
protocol of a single-arm, prospective phase Ib/II trial. Front
Pharmacol. 16:15624812025. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang X, Qi B and Chen J: Clinical
application and drug resistance mechanism of gemcitabine. Front
Cell Dev Biol. 13:17027202025. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zou L, Chen J, Bai X, Wang Y, Lu C, Wang
Q, Tuerhong S, Li M, Zheng Q, Meng F and Du J: Tumor-penetrating
peptide boosts bispecific T-cell engager antitumor efficacy for the
pancreatic cancer. Front Immunol. 16:16937552025. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang W, Xiang Y, Ren H, Liu Y, Wang Q,
Ran M, Zhou W, Tian L, Zheng X, Qiao C, et al: The tumor microbiome
in cancer progression: Mechanisms and therapeutic potential. Mol
Cancer. 24:1952025. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cao Y, Xia H, Tan X, Shi C, Ma Y, Meng D,
Zhou M, Lv Z, Wang S and Jin Y: Intratumoural microbiota: A new
frontier in cancer development and therapy. Signal Transduct Target
Ther. 9:152024. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang L, Li A, Wang Y and Zhang Y:
Intratumoral microbiota: Roles in cancer initiation, development
and therapeutic efficacy. Signal Transduct Target Ther. 8:352023.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jiang Y, Huang Y, Hu Y, Yang Y, You F, Hu
Q, Li X and Zhao Z: Banxia Xiexin Decoction delays
colitis-to-cancer transition by inhibiting E-cadherin/β-catenin
pathway via Fusobacterium nucleatum FadA. J Ethnopharmacol.
328:1179322024. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang L, Leng XX, Qi J, Wang N, Han JX,
Tao ZH, Zhuang ZY, Ren Y, Xie YL, Jiang SS, et al: The adhesin RadD
enhances Fusobacterium nucleatum tumour colonization and
colorectal carcinogenesis. Nat Microbiol. 9:2292–2307. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Stein-Thoeringer CK, Saini NY, Zamir E,
Blumenberg V, Schubert ML, Mor U, Fante MA, Schmidt S, Hayase E,
Hayase T, et al: A non-antibiotic-disrupted gut microbiome is
associated with clinical responses to CD19-CAR-T cell cancer
immunotherapy. Nat Med. 29:906–916. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Leonov G, Starodubova A, Makhnach O,
Goldshtein D and Salikhova D: Intratumoral Microbiome: Impact on
cancer progression and cellular immunotherapy. Cancers (Basel).
18:1002025. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cheng H, Guo H, Wen C, Sun G, Tang F and
Li Y: The dual role of gut microbiota in pancreatic cancer: New
insights into onset and treatment. Ther Adv Med Oncol.
17:175883592513248822025. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pushalkar S, Hundeyin M, Daley D,
Zambirinis CP, Kurz E, Mishra A, Mohan N, Aykut B, Usyk M, Torres
LE, et al: The pancreatic cancer microbiome promotes oncogenesis by
induction of innate and adaptive immune suppression. Cancer Discov.
8:403–416. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cruz MS, Tintelnot J and Gagliani N: Roles
of microbiota in pancreatic cancer development and treatment. Gut
Microbes. 16:23202802024. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bautista J, Bedón-Galarza R,
Martínez-Hidalgo F, Masache-Cruz M, Benítez-Núñez M,
Valencia-Arroyo C and López-Cortés A: Decoding the microbial
blueprint of pancreatic cancer. Front Med (Lausanne).
13:17375822026. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yuan Y, Zhang W and Wang D: Targeting the
gut-pancreatic axis: Microbial modulation of immunotherapy in
pancreatic cancer. Front Immunol. 17:16823902026. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lyman MR, Mitchell JT, Raghavan S,
Kagohara LT, Huff AL, Haldar SD, Shin SM, Guinn S, Barrett B,
Longway G, et al: Spatial proteomics and transcriptomics reveal
early immune cell organization in pancreatic intraepithelial
neoplasia. JCI Insight. 10:e1915952025. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sun Z, Xiong C, Teh SW, Lim JCW, Kumar S
and Thilakavathy K: Mechanisms of oral bacterial virulence factors
in pancreatic cancer. Front Cell Infect Microbiol. 9:4122019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Meng Y, Wu F, Kwak S, Wang C, Usyk M,
Freedman ND, Huang WY, Um CY, Gonda TA, Oberstein PE, et al: Oral
bacterial and fungal microbiome and subsequent risk for pancreatic
cancer. JAMA Oncol. 11:1331–1340. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jiang H, Li L, Bao Y, Cao X and Ma L:
Microbiota in tumors: New factor influencing cancer development.
Cancer Gene Therapy. 31:1773–1785. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Toraya S, Uehara O, Hiraki D, Harada F,
Neopane P, Morikawa T, Takai R, Yoshida K, Matsuoka H, Kitaichi N,
et al: Curcumin inhibits the expression of proinflammatory
mediators and MMP-9 in gingival epithelial cells stimulated for a
prolonged period with lipopolysaccharides derived from
Porphyromonas gingivalis. Odontology. 108:16–24. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Maquera-Huacho PM, Spolidorio DP, Manthey
J and Grenier D: Effect of hesperidin on barrier function and
reactive oxygen species production in an oral epithelial cell
model, and on secretion of macrophage-derived inflammatory
mediators during Porphyromonas gingivalis infection. Int J
Mol Sci. 24:103892023. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wei W, Li CX, Li MQ, Tan XR and Gong ZC:
Porphyromonas gingivalis promotes oral carcinogenesis
through the NDK-ATP-P2X7 signal axis: An in vitro experimental
study. Arch Oral Biol. 177:1063322025. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Inaba H, Sugita H, Kuboniwa M, Iwai S,
Hamada M, Noda T, Morisaki I, Lamont RJ and Amano A:
Porphyromonas gingivalis promotes invasion of oral squamous
cell carcinoma through induction of proMMP9 and its activation.
Cell Microbiol. 16:131–145. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gao Z, Weng X, Yu D, Pan Z, Zhao M, Cheng
B and Li Z: Porphyromonas gingivalis-derived
lipopolysaccharide promotes glioma cell proliferation and migration
via activating Akt signaling pathways. Cells. 11:40882022.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yaghoobi H, Bandehpour M and Kazemi B:
Apoptotic effects of the B subunit of bacterial cytolethal
distending toxin on the A549 lung cancer cell line. Asian Pac J
Cancer Prev. 17:299–304. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shenker BJ, Boesze-Battaglia K, Scuron MD,
Walker LP, Zekavat A and Dlakić M: The toxicity of the
Aggregatibacter actinomycetemcomitans cytolethal distending
toxin correlates with its phosphatidylinositol-3,4,5-triphosphate
phosphatase activity. Cell Microbiol. 18:223–243. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shenker BJ, Dlakic M, Walker LP, Besack D,
Jaffe E, LaBelle E and Boesze-Battaglia K: A novel mode of action
for a microbial-derived immunotoxin: The cytolethal distending
toxin subunit B exhibits phosphatidylinositol 3,4,5-triphosphate
phosphatase activity. J Immunol. 178:5099–5108. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jinadasa RN, Bloom SE, Weiss RS and
Duhamel GE: Cytolethal distending toxin: A conserved bacterial
genotoxin that blocks cell cycle progression, leading to apoptosis
of a broad range of mammalian cell lineages. Microbiology
(Reading). 157:1851–1875. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ma J, Fu S, Tan J, Han Y, Chen Y, Deng X,
Shen H, Zeng S, Peng Y and Cai C: Mechanistic foundations of
KRAS-driven tumor ecosystems: Integrating Crosstalk among immune,
metabolic, microbial, and stromal microenvironment. Adv Sci
(Weinh). 12:e027142025. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Diehl AC, Hannan LM, Zhen DB, Coveler AL,
King G, Cohen SA, Harris WP, Shankaran V, Wong KM, Green S, et al:
KRAS mutation variants and Co-occurring PI3K pathway alterations
impact survival for patients with pancreatic ductal
adenocarcinomas. Oncologist. 27:1025–1033. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
McDaid WJ, Wilson L, Adderley H,
Martinez-Lopez A, Baker MJ, Searle J, Ginn L, Budden T, Aldea M,
Marinello A, et al: The PI3K-AKT-mTOR axis persists as a
therapeutic dependency in KRAS(G12D)-driven non-small cell lung
cancer. Mol Cancer. 23:2532024. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Saba E, Farhat M, Daoud A, Khashan A,
Forkush E, Menahem NH, Makkawi H, Pandi K, Angabo S, Kawasaki H, et
al: Oral bacteria accelerate pancreatic cancer development in mice.
Gut. 73:770–786. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Riquelme E, Zhang Y, Zhang L, Montiel M,
Zoltan M, Dong W, Quesada P, Sahin I, Chandra V, San Lucas A, et
al: Tumor microbiome diversity and composition influence pancreatic
cancer outcomes. Cell. 178:795–806.e712. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Aykut B, Pushalkar S, Chen R, Li Q,
Abengozar R, Kim JI, Shadaloey SA, Wu D, Preiss P, Verma N, et al:
The fungal mycobiome promotes pancreatic oncogenesis via activation
of MBL. Nature. 574:264–267. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Arikath K, Batra SK and Ponnusamy MP:
Unveiling the gut-pancreas axis: Microbial influence on stemness
and tumor microenvironment of PDAC. Stem Cells. 44:sxaf0642026.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Half E, Keren N, Reshef L, Dorfman T,
Lachter I, Kluger Y, Reshef N, Knobler H, Maor Y, Stein A, et al:
Fecal microbiome signatures of pancreatic cancer patients. Sci Rep.
9:168012019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Guo X and Shao Y: Role of the oral-gut
microbiota axis in pancreatic cancer: A new perspective on tumor
pathophysiology, diagnosis, and treatment. Mol Med. 31:1032025.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sun J, Chen F and Wu G: Potential effects
of gut microbiota on host cancers: Focus on immunity, DNA damage,
cellular pathways, and anticancer therapy. ISME J. 17:1535–1551.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wu C, Li M and Chen W: Characteristics of
gut microbiota in cerulein-induced chronic pancreatitis. Diabetes
Metab Syndr Obes. 14:285–294. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yang Q, Zhang J and Zhu Y: Potential roles
of the gut microbiota in pancreatic carcinogenesis and
therapeutics. Front Cell Infect Microbiol. 12:8720192022.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
He Y, Shaoyong W, Chen Y, Li M, Gan Y, Sun
L, Liu Y, Wang Y and Jin M: The functions of gut
microbiota-mediated bile acid metabolism in intestinal immunity. J
Adv Res. 80:351–370. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Nagata N, Nishijima S, Kojima Y, Hisada Y,
Imbe K, Miyoshi-Akiyama T, Suda W, Kimura M, Aoki R, Sekine K, et
al: Metagenomic identification of microbial signatures predicting
pancreatic cancer from a multinational study. Gastroenterology.
163:222–238. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Tang W, Li F, Zheng H, Zhou S, Li C, Xu X
and Fu J: Unveiling hidden players: The role of intratumoral
microbiota in gastrointestinal cancer dynamics. J Cancer Res Clin
Oncol. 152:152025. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kunovsky L, Dite P, Jabandziev P, Dolina
J, Vaculova J, Blaho M, Bojkova M, Dvorackova J, Uvirova M, Kala Z
and Trna J: Helicobacter pylori infection and other bacteria
in pancreatic cancer and autoimmune pancreatitis. World J
Gastrointest Oncol. 13:835–844. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Fakruddin M, Chowdhury Z, Suprova SN, Ul
Islam B, Sultana Jime J, Bulbul N, Anam MB, Bin Mannan S and
Shishir MA: Microbial influences: The Microbiome's impact on
pancreatic cancer development and progression. Curr Pharm
Biotechnol. Apr 18–2025.doi: 10.2174/0113892010356542250407143257
(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zheng SH, Li KZ, Feng G, Wang YT, Wang JN,
Li SQ and Sun YD: Gut microbiota reshaping the pancreatic cancer
immune microenvironment: New avenues for immunotherapy. Mol Cancer.
24:3132025. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
D'Antonio DL, Zenoniani A, Umme S,
Piattelli A and Curia MC: Intratumoral Fusobacterium
nucleatum in pancreatic cancer: Current and future
perspectives. Pathogens. 14:22024. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Udayasuryan B, Ahmad RN, Nguyen TTD, Umaña
A, Monét Roberts L, Sobol P, Jones SD, Munson JM, Slade DJ and
Verbridge SS: Fusobacterium nucleatum induces proliferation
and migration in pancreatic cancer cells through host autocrine and
paracrine signaling. Sci Signal. 15:eabn49482022. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Pignatelli P, Nuccio F, Piattelli A and
Curia MC: The role of Fusobacterium nucleatum in oral and
colorectal carcinogenesis. Microorganisms. 11:23582023. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Wang B, Deng J, Donati V, Merali N,
Frampton AE, Giovannetti E and Deng D: The roles and interactions
of Porphyromonas gingivalis and Fusobacterium
nucleatum in oral and gastrointestinal carcinogenesis: A
narrative review. Pathogens. 13:932024. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Wan Jiun T, Taib H, Majdiah Wan Mohamad W,
Mohamad S and Syamimee Wan Ghazali W: Periodontal health status,
Porphyromonas gingivalis and anti-cyclic citrullinated
peptide antibodies among rheumatoid arthritis patients. Int
Immunopharmacol. 124:1109402023. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Fiordaliso M, Pala B, Marincola G,
Piscione M, Savino L, Mazzone M, Di Marcantonio MC and Mincione G:
Biliary stents can modify the microbiota and promote the
progression of pancreatic cancer. Front Oncol. 16:16336112026.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Shimosaka M, Kondo J, Sonoda M, Kawaguchi
R, Noda E, Nishikori K, Ogata A, Takamatsu S, Sasai K, Akita H, et
al: Invasion of pancreatic ductal epithelial cells by
Enterococcus faecalis is mediated by fibronectin and
enterococcal fibronectin-binding protein A. Sci Rep. 15:25852025.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Luo D, Chen Q, Li Y, Yang J, Tao Y, Ji L
and Gong X: Microbiome-metabolome interplay in pancreatic cancer
progression: Insights from multi-omics analysis. Mol Cancer.
24:2402025. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Xia K, Zhou Y, Wang W and Cai Y:
Streptococcus anginosus: The potential role in the
progression of gastric cancer. J Cancer Res Clin Oncol.
151:1432025. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Tan Q, Ma X, Yang B, Liu Y, Xie Y, Wang X,
Yuan W and Ma J: Periodontitis pathogen Porphyromonas
gingivalis promotes pancreatic tumorigenesis via neutrophil
elastase from tumor-associated neutrophils. Gut Microbes.
14:20737852022. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zhang H, Tian Y, Xu C, Chen M, Xiang Z, Gu
L, Xue H and Xu Q: Crosstalk between gut microbiotas and fatty acid
metabolism in colorectal cancer. Cell Death Discov. 11:782025.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Zhang C, Wang Y, He M, Wang C, Cao K,
Zhong Y, Wang X, Yang M, Zhang G, Lu J, et al: Mannose enhances
immunotherapy efficacy in ovarian cancer by modulating gut
microbial metabolites. Cancer Res. 85:2468–2484. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Gao Y, Xu P, Sun D, Jiang Y, Lin XL, Han
T, Yu J, Sheng C, Chen H, Hong J, et al: Faecalibacterium
prausnitzii abrogates intestinal toxicity and promotes tumor
immunity to increase the efficacy of Dual CTLA4 and PD-1 checkpoint
blockade. Cancer Res. 83:3710–3725. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Liang Y, Du M, Li X, Gao J, Li Q, Li H, Li
J, Gao X, Cong H, Huang Y, et al: Upregulation of Lactobacillus
spp. in gut microbiota as a novel mechanism for environmental
eustress-induced anti-pancreatic cancer effects. Gut Microbes.
17:24703722025. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Chen X, Li Y, Wei G, Zheng Z, Liu W, Li M,
Dai X, Liu B, Zhong R and Ye J: The role of Akkermansia
muciniphila in cancer: Mechanisms, therapeutic potential, and
challenges. IMetaOmics. 2:e700102025. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Liu Y, Li Y, Ma H, Deng S and Cheng C:
Mechanistic insights into pancreatic cancer progression from
circadian rhythm disruption and gut microbiota dysbiosis (Review).
Int J Mol Med. 57:732026. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Fan L, Xu C, Ge Q, Lin Y, Wong CC, Qi Y,
Ye B, Lian Q, Zhuo W, Si J, et al: A. Muciniphila suppresses
colorectal tumorigenesis by inducing TLR2/NLRP3-mediated M1-like
TAMs. Cancer Immunol Res. 9:1111–1124. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Li N, Bai C, Zhao L, Sun Z, Ge Y and Li X:
The relationship between gut microbiome features and chemotherapy
response in gastrointestinal cancer. Front Oncol. 11:7816972021.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Gubernatorova EO, Gorshkova EA, Bondareva
MA, Podosokorskaya OA, Sheynova AD, Yakovleva AS,
Bonch-Osmolovskaya EA, Nedospasov SA, Kruglov AA and Drutskaya MS:
Akkermansia muciniphila-friend or foe in colorectal cancer?
Front Immunol. 14:13037952023. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Kharofa J, Haslam D, Wilkinson R, Weiss A,
Patel S, Wang K, Esslinger H, Olowokure O, Sohal D, Wilson G, et
al: Analysis of the fecal metagenome in long-term survivors of
pancreas cancer. Cancer. 129:1986–1994. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Tavanaeian S, Feizabadi MM, Falsafi S,
Aghdaei HA and Houri H: Oral and fecal microbiome alterations in
pancreatic cancer: Insights into potential diagnostic biomarkers.
BMC Microbiol. 25:6242025. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Li S, Duan Y, Luo S, Zhou F, Wu Q and Lu
Z: Short-chain fatty acids and cancer. Trends Cancer. 11:154–168.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Sethi V, Kurtom S, Tarique M, Lavania S,
Malchiodi Z, Hellmund L, Zhang L, Sharma U, Giri B, Garg B, et al:
Gut Microbiota promotes tumor growth in mice by modulating immune
response. Gastroenterology. 155:33–37.e36. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Halle-Smith JM, Pearce H, Nicol S, Hall
LA, Powell-Brett SF, Beggs AD, Iqbal T, Moss P and Roberts KJ:
Involvement of the gut microbiome in the local and systemic immune
response to pancreatic ductal adenocarcinoma. Cancers (Basel).
16:9962024. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
McAllister F, Bailey JM, Alsina J, Nirschl
CJ, Sharma R, Fan H, Rattigan Y, Roeser JC, Lankapalli RH, Zhang H,
et al: Oncogenic Kras activates a hematopoietic-to-epithelial IL-17
signaling axis in preinvasive pancreatic neoplasia. Cancer Cell.
25:621–637. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Gu H, Deng W, Zheng Z, Wu K and Sun F:
CCL2 produced by pancreatic ductal adenocarcinoma is essential for
the accumulation and activation of monocytic myeloid-derived
suppressor cells. Immun Inflamm Dis. 9:1686–1695. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Schweickert PG, Yang Y, White EE,
Cresswell GM, Elzey BD, Ratliff TL, Arumugam P, Antoniak S, Mackman
N, Flick MJ, et al: Thrombin-PAR1 signaling in pancreatic cancer
promotes an immunosuppressive microenvironment. J Thromb Haemost.
19:161–172. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Zambirinis CP, Levie E, Nguy S, Avanzi A,
Barilla R, Xu Y, Seifert L, Daley D, Greco SH, Deutsch M, et al:
TLR9 ligation in pancreatic stellate cells promotes tumorigenesis.
J Exp Med. 212:2077–2094. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Temel HY, Kaymak Ö, Kaplan S, Bahcivanci
B, Gkoutos GV and Acharjee A: Role of microbiota and
microbiota-derived short-chain fatty acids in PDAC. Cancer Med.
12:5661–5675. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Nogal A, Louca P, Zhang X, Wells PM,
Steves CJ, Spector TD, Falchi M, Valdes AM and Menni C: Circulating
levels of the short-chain fatty acid acetate mediate the effect of
the gut microbiome on visceral fat. Front Microbiol. 12:7113592021.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Hezaveh K, Shinde RS, Klötgen A, Halaby
MJ, Lamorte S, Ciudad MT, Quevedo R, Neufeld L, Liu ZQ, Jin R, et
al: Tryptophan-derived microbial metabolites activate the aryl
hydrocarbon receptor in tumor-associated macrophages to suppress
anti-tumor immunity. Immunity. 55:324–340.e8. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Bautista J, Lamas-Maceiras M,
Hidalgo-Tinoco C, Guerra-Guerrero A, Betancourt-Velarde A and
López-Cortés A: Gut microbiome-driven colorectal cancer via immune,
metabolic, neural, and endocrine axes reprogramming. NPJ Biofilms
Microbiomes. 12:212026. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Gapstur SM, Gann PH, Lowe W, Liu K,
Colangelo L and Dyer A: Abnormal glucose metabolism and pancreatic
cancer mortality. JAMA. 283:2552–2558. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Li D: Diabetes and pancreatic cancer. Mol
Carcinog. 51:64–74. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Shen B, Li Y, Sheng CS, Liu L, Hou T, Xia
N, Sun S, Miao Y, Pang Y, Gu K, et al: Association between age at
diabetes onset or diabetes duration and subsequent risk of
pancreatic cancer: Results from a longitudinal cohort and mendelian
randomization study. Lancet Reg Health West Pac.
30:1005962023.PubMed/NCBI
|
|
92
|
Sapoor S, Nageh M, Shalma NM, Sharaf R,
Haroun N, Salama E, Pratama Umar T, Sharma S and Sayad R:
Bidirectional relationship between pancreatic cancer and diabetes
mellitus: A comprehensive literature review. Ann Med Surg (Lond).
86:3522–3529. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Jiménez-Cortegana C, López-Saavedra A,
Sánchez-Jiménez F, Pérez-Pérez A, Castiñeiras J, Virizuela-Echaburu
JA, de la Cruz-Merino L and Sánchez-Margalet V: Leptin, Both bad
and good actor in cancer. Biomolecules. 11:9132021. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Jiang J, Fan Y, Zhang W, Shen Y, Liu T,
Yao M, Gu J, Tu H and Gan Y: Adiponectin suppresses human
pancreatic cancer growth through attenuating the β-catenin
signaling pathway. Int J Biol Sci. 15:253–264. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Kern PA, Di Gregorio GB, Lu T, Rassouli N
and Ranganathan G: Adiponectin expression from human adipose
tissue: Relation to obesity, insulin resistance, and tumor necrosis
factor-alpha expression. Diabetes. 52:1779–1785. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Ruze R, Song J, Yin X, Chen Y, Xu R, Wang
C and Zhao Y: Mechanisms of obesity- and diabetes mellitus-related
pancreatic carcinogenesis: A comprehensive and systematic review.
Signal Transduct Target Ther. 8:1392023. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Ho WJ, Jaffee EM and Zheng L: The tumour
microenvironment in pancreatic cancer-clinical challenges and
opportunities. Nat Rev Clin Oncol. 17:527–540. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Kounatidis D, Vallianou NG, Karampela I,
Grivakou E and Dalamaga M: The intricate role of adipokines in
cancer-related signaling and the tumor microenvironment: Insights
for future research. Semin Cancer Biol. 113:130–150. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Chang HH, Moro A, Takakura K, Su HY, Mo A,
Nakanishi M, Waldron RT, French SW, Dawson DW, Hines OJ, et al:
Incidence of pancreatic cancer is dramatically increased by a high
fat, high calorie diet in KrasG12D mice. PLoS One. 12:e01844552017.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Chen S, Zhang J, Chen J, Wang Y, Zhou S,
Huang L, Bai Y, Peng C, Shen B, Chen H and Tian Y: RER1 enhances
carcinogenesis and stemness of pancreatic cancer under hypoxic
environment. J Exp Clin Cancer Res. 38:152019. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Dai E, Han L, Liu J, Xie Y, Kroemer G,
Klionsky DJ, Zeh HJ, Kang R, Wang J and Tang D: Autophagy-dependent
ferroptosis drives tumor-associated macrophage polarization via
release and uptake of oncogenic KRAS protein. Autophagy.
16:2069–2083. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Otto L, Rahn S, Daunke T, Walter F, Winter
E, Möller JL, Rose-John S, Wesch D, Schäfer H and Sebens S:
Initiation of pancreatic cancer: The interplay of hyperglycemia and
macrophages promotes the acquisition of malignancy-associated
properties in pancreatic ductal epithelial cells. Int J Mol Sci.
22:50862021. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Alifano M, Daffré E, Iannelli A, Brouchet
L, Falcoz PE, Le Pimpec Barthes F, Bernard A, Pages PB, Thomas PA,
Dahan M and Porcher R: The reality of lung cancer paradox: The
impact of body mass index on long-term survival of resected lung
cancer. A french nationwide analysis from the Epithor database.
Cancers. 13:45742021. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Petrelli F, Cortellini A, Indini A,
Tomasello G, Ghidini M, Nigro O, Salati M, Dottorini L, Iaculli A,
Varricchio A, et al: Association of obesity with survival outcomes
in patients with cancer: A systematic review and Meta-analysis.
JAMA Netw Open. 4:e2135202021. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Delaye M, Rousseau A, Mailly-Giacchetti L,
Assoun S, Sokol H and Neuzillet C: Obesity, cancer, and response to
immune checkpoint inhibitors: Could the gut microbiota be the
mechanistic link? Pharmacol Ther. 247:1084422023. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Piening A, Ebert E, Gottlieb C, Khojandi
N, Kuehm LM, Hoft SG, Pyles KD, McCommis KS, DiPaolo RJ, Ferris ST,
et al: Obesity-related T cell dysfunction impairs
immunosurveillance and increases cancer risk. Nat Commun.
15:28352024. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Lee B, Han HS, Yoon YS, Park Y, Kang M and
Kim J: ‘Obesity paradox’ as a new insight from long-term survivors
in pancreatic cancer patients. HPB (Oxford). 27:922–929. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Mirji G, Worth A, Bhat SA, El Sayed M,
Kannan T, Goldman AR, Tang HY, Liu Q, Auslander N, Dang CV, et al:
The microbiome-derived metabolite TMAO drives immune activation and
boosts responses to immune checkpoint blockade in pancreatic
cancer. Sci Immunol. 7:eabn07042022. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Nywening TM, Wang-Gillam A, Sanford DE,
Belt BA, Panni RZ, Cusworth BM, Toriola AT, Nieman RK, Worley LA,
Yano M and Fowler KJ: Targeting tumour-associated macrophages with
CCR2 inhibition in combination with FOLFIRINOX in patients with
borderline resectable and locally advanced pancreatic cancer: A
single-centre, open-label, dose-finding, non-randomised, phase 1b
trial. Lancet Oncol. 17:651–662. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Carpenter E, Nelson S, Bednar F, Cho C,
Nathan H, Sahai V, di Magliano MP and Frankel TL: Immunotherapy for
pancreatic ductal adenocarcinoma. J Surg Oncol. 123:751–759. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Thomas AM, Santarsiero LM, Lutz ER,
Armstrong TD, Chen YC, Huang LQ, Laheru DA, Goggins M, Hruban RH
and Jaffee EM: Mesothelin-specific CD8(+) T cell responses provide
evidence of in vivo cross-priming by antigen-presenting cells in
vaccinated pancreatic cancer patients. J Exp Med. 200:297–306.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Sethna Z, Guasp P, Reiche C, Milighetti M,
Ceglia N, Patterson E, Lihm J, Payne G, Lyudovyk O, Rojas LA, et
al: RNA neoantigen vaccines prime long-lived CD8+ T
cells in pancreatic cancer. Nature. 639:1042–1051. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Jiang S, Li H, Zhang L, Mu W, Zhang Y,
Chen T, Wu J, Tang H, Zheng S, Liu Y, et al: Generic diagramming
platform (GDP): A comprehensive database of high-quality biomedical
graphics. Nucleic Acids Res. 53:D1670–D1676. 2025. View Article : Google Scholar : PubMed/NCBI
|
